K972877

510(k) Premarket Notification UltraSafe® Injection System Model C200 Injector with Needle Guard

FEB 26 1998

9.0 Summary of Safety and Effectiveness

3.1 Safety Syringes Contact Person

David Mitchell Safety Syringes, Inc. 250 West Colorado Blvd. Suite # 101 Arcadia, CA 91007 (626) 821.1121 Phone (626) 821.1009 Fax

9.2 Device Name

UltraSafe® Injection System, Model C200 Injector with Needle Guard

9.3 Predicate Devices

Safety Syringes UltraSafe® Aspirating Syringe - K944425 Sanofi-Winthrop Injector - Pre-amendment

9.4 Product Description and Function

The UltraSafe® Model C200 Injector with Needle Guard is a product which is intended to be used with a sterile medication cartridge with needle to deliver medication from the cartridge into the tissues of the patient. The device is totally disposable and is equipped with a needle shield which consists of a safety guard that can be snapped into place after use of a syringe, thus protecting the caregiver by eliminating the need to recap the needle, and minimizing accidental needle stick injuries during disposal of the syringe/needle

9.5 <u>Comparison to Predicate Devices/Equivalence</u>

Descriptive Comparison to Legally Marketed Devices
Model C200 Injectors with Needle Guard are intended to be
used to deliver medication from a cartridge. The guard

requires a two-handed action in order to cover the needle point after use.

The Model C200 needle guard has been tested and found to have considerably greater strength than the predicate device. The C200 Injector is as easy to assemble and use as the Sanofi-Winthrop Injector.

With the Model ©200 needle guard in the "ready-to-use" position, it provides the same useable needle length as an unguarded needle. The user can perform typical hypodermic procedures equivalently to standard, unguarded needles.

9.6 Comparison of Materials

The UltraSate® Injection System, Model C200 Injector is made of K-Resin KR01, KR03, and ABS Resin which are the same materials as the Safety Syringes predicate device.

9.7 Safety and Efficacy Information

Biocompatibility:

The UltraSafe® Injection System, Model C200 Injector uses the same materials as the Safety Syringes predicate device. The materials have passed biocompatibility tests.

Labeled Warning Statements:

Hands must remain behind the needle at all times during use and disposal.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 26 1998

Mr. Anthony R. Perez CEO & President Safety Syringes, Incorporated 250 West Colorado Boulevard, Suite 101 Arcadia, California 91007

Re: K972877

Trade Name: UltraSafe® Injection System Model C200

Injector with Needle Guard

Regulatory Class: II Product Code: FMF

Dated: January 6, 1998 Received: January 7, 1998

Dear Mr. Perez:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does

not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Singerely

Timothy A. Ulatowski

Director

Division of Dental, Infection Control and General Hospital Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

					Page_1	_ of1	
510(k) Number	(if known):	K972877					
Device Name:	UltraSafe®	Injection System	Model C200 I	njector With Needle	Guard		
Indications For	Use:						
needle in place	while admini		on. The guard	designed to hold a st is intended to proted nit.			
cartridge to deli	ver medication	on from the cartrid posal. This device	dge to the tissu	d Sanofi-Winthrop Ca ue of a patient, and is wide range of patie	s equipped wit	h a shield th	nat
Divisi	ion Sign-Off) on of Dantal, It	fection Control, Devices					
(PLEASE	DO NOT W	RITE BELOW TH	IIS LINE - CON	NTINUE ON ANOTH	ER PAGE IF N	NEEDED)	
Concurrence of	CDRH, Office	of Device Evalu	ation (ODE)				
Prescription Use Per 21 CFR 801			OR	Over-The-Cou	ınter Use		

(Optional Format 1-2-96)